Patient enrollment

From January 1, 2012 to December 31, 2020, 192 patients with ovarian metastasis were screened from 15,315 GC patients. After excluding 101 patients who did not receive ovarian resection or biopsy and 17 patients with insufficient tumor volume, 74 patients were finally enrolled for this study (Fig. 1a). A total of 65 primary gastric and 73 ovarian metastatic tumor samples were collected from the enrolled patients, including 64 pairs matched primary gastric and metastatic ovarian tumor samples. Follow-up data were obtained by phone and through an out-patient clinical database. The last follow-up occurred in January 2022, and follow-up data were available in 71 (71/74, 95.9%) patients. The overall survival (OS) time was calculated from the date of diagnosis to the last day of follow-up or the date of death. Patients who received paclitaxel-based chemotherapy were evaluated for therapeutic efficacy. The response to treatment was evaluated according to the criteria of Response Evaluation Criteria in Solid Tumors (RECIST 1.1). Patients with complete response (CR) or partial response (PR) were considered as effective, and patients with stable disease (SD) or progressive disease (PD) were considered as ineffective.